Aktiesnakken — November 2011
-
en emission i velo er insane
-
de har jo lige været igennem en?
-
-
Produktet er godt nok, ser ud til at være bedre end Prograf http://npinvestor.dk/nyheder/veloxis-pharma-fremlaegger-fase-3-data-paa-aarsmoede-i-american-society-235053.aspx
-
Go aften,nåhh si endte på1,00 tror du den vil stige fremover?
-
is
-
Når man som jeg både har vestas og velo føler man sig temmelig slukøret idag
-
Hmmmm....men om det holder i morgen...hvad skal du så med Aktiekoppen til ?? Du kan vel kun drikke af en ad gangen. ;0)
in the key U.S. Transplant market. US commercialization costs will likely require USD 50-60 million (DKK 250-350 million
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind